Conatus Adds $7.5M, Closes Series B Round
San Diego’s Conatus Pharmaceuticals says it has closed the Series B round of funding that began in February with a $7.5 million investment by MPM Capital of South San Francisco, CA. In a statement yesterday, the company says it has raised a total of $32.5 million in this round. Conatus plans to use the proceeds to advance development of CTS-1027, a new drug candidate for treating hepatitis C that the company licensed from F. Hoffman-La Roche, and to evaluate compounds acquired from Idun Pharmaceuticals last year. The hepatitis C compound is currently in multiple mid-stage clinical trials.